amoxipen - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

tamoxifen sandoz

sandoz new zealand limited - tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg; - film coated tablet - 20 mg - active: tamoxifen citrate 30.4mg equivalent to tamoxifen 20 mg excipient: hypromellose lactose monohydrate macrogol 4000 magnesium stearate microcrystalline cellulose povidone sodium starch glycolate titanium dioxide

United States - English - NLM (National Library of Medicine)

tamoxifen citrate tablet

nucare pharmaceuticals,inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen citrate tablets, usp are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. tamoxifen citrate tablets, usp are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets, usp are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to b

Australia - English - Department of Health (Therapeutic Goods Administration)

tamoxifen lupin tamoxifen (as citrate) 20 mg tablet blister pack

southern cross pharma pty ltd - tamoxifen citrate, quantity: 30.34 mg (equivalent: tamoxifen, qty 20 mg) - tablet - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; brilliant scarlet 4r; povidone - treatment of breast cancer tamoxifen lupin is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk tamoxifen lupin is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

United States - English - NLM (National Library of Medicine)

tamoxifen citrate- tamoxifen citrate tablet

andrx pharmaceuticals, inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tablet - 10 mg - metastatic breast cancer: tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. adjuvant treatment of breast cancer: tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with 4 or more positive axillary nodes. tamoxifen is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whet

United States - English - NLM (National Library of Medicine)

tamoxifen citrate tablet

remedyrepack inc. - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy. tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen- and progesterone-receptor values may help to predict whether adjuvant